SCHEMBL4423401

SCHEMBL4423401

COc1ccc(C2C(=O)c3ccc(OC)cc3C2c2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.57
EDNRA P25101 3/20 0.51
ALDH1A1 P00352 1/20 0.51
NPC1 O15118 2/20 0.50
MAPT P10636 2/20 0.50
RAB9A P51151 2/20 0.50
TP53 P04637 1/20 0.50
HPGD P15428 1/20 0.50
MAOA P21397 1/20 0.50
PTGS2 P35354 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CYP19A1 P11511 5/20 0.49
EDNRB P24530 2/20 0.49
MAOB P27338 3/20 0.46
CYP3A4 P08684 1/20 0.44
ABCB1 P08183 1/20 0.43
AR P10275 1/20 0.43
ABCG2 Q9UNQ0 1/20 0.43
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28414867 0.97 ESR2 (0.53) ESR2EDNRAALDH1A1NPC1MAPT
SCHEMBL9862488 0.82 ESR2 (0.53) ESR2EDNRAALDH1A1NPC1MAPT
SCHEMBL4420199 0.79 EDNRA (0.48) ESR2EDNRAALDH1A1NPC1MAPT
SCHEMBL29397268 0.78 CYP19A1 (0.57) ESR2ALDH1A1SMN1; SMN2CYP19A1MAOB
SCHEMBL30638795 0.78 CYP19A1 (0.57) ESR2ALDH1A1SMN1; SMN2CYP19A1MAOB
SCHEMBL28607133 0.76 CYP19A1 (0.48) ALDH1A1NPC1MAPTTP53HPGD
SCHEMBL10967159 0.76 ALDH1A1 (0.75) EDNRAALDH1A1NPC1MAPTRAB9A
SCHEMBL17637164 0.75 KDM4E (0.58) ESR2ALDH1A1NPC1MAPTRAB9A
SCHEMBL29475777 0.75 RAB9A (0.55) EDNRAALDH1A1NPC1MAPTRAB9A
SCHEMBL319627 0.74 ESR2 (0.49) ESR2EDNRAALDH1A1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090326018-A1 2-Phenyl indene derivatives useful as estrogen receptor ligands KARO BIO AB (SE) 2009-12-31 US disclosed
US-20090326018-A1 2-Phenyl indene derivatives useful as estrogen receptor ligands KARO BIO AB (SE) 2009-12-31 US disclosed
US-20090326018-A1 2-Phenyl indene derivatives useful as estrogen receptor ligands KARO BIO AB (SE) 2009-12-31 US disclosed
EP-2074102-A1 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2009-07-01 EP disclosed
WO-2008043567-A1 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2008-04-17 WO disclosed
WO-2008043567-A1 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326018-A1 2-Phenyl indene derivatives useful as estrogen receptor ligands ESR1, GPER1, ESR2 ESR2 3/4885EDNRA 18/4885ALDH1A1 1020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.